Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
AbbVie
54 Articles Available
0
3
Can't find what you're looking for? Try our
advanced search
.
Collaboration
AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets
PR-M01-23-01
Regulatory Compliance
Addressing Regulatory Challenges for Ophthalmic Combination Products
PAO-04-022-CL-09
Aseptic Processing
Unique Manufacturing Challenges Associated with Sterile Eye Ointments
PAO-04-022-CL-04
Hot Melt Extrusion
Streamline HME Projects with Early Partner Engagement
PAO-08-21-CL-06
Drug Update
AbbVie Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
PR-M07-21-011
M&A
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma
PR-M07-21-01
Body Contouring
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
PR-M05-21-008
Croatia
Healthcare in Croatia
PAO-04-22-R221-59
Lyophilization
Shorten Time to Market with New Data-Driven Lyophilization Process
PAO-03-21-CL-07
Partnership
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
PR-M09-20-NI-06
M&A
AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan
PR-M05-20-NI-012
Business
AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisition
PR-M01-20-NI-016
Collaboration
AbbVie and Scripps Research Announce Collaboration to Develop a Broad Range of New Therapeutics
PR-M12-19-NI-021
M&A
AbbVie Issues Large Bond to Finance Allergan Merger
PAO-M11-19-NI-006
FDA Approval
AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis
PR-M08-19-NI-073
M&A
AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
PR-M07-19-NI-038
M&A
AbbVie to Acquire Allergan for $63 Billion
PR-M06-19-NI-052
ADC
Speeding up ADC Development With the Right Partner Organization
PAP-Q2-2019-CL-001
FDA Approval
FDA Approves Venetoclax for CLL and SLL
PR-M05-19-NI-057
Legal
AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
PR-M05-19-NI-056
Announcement
AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer
PR-M05-19-NI-054
Donation
AbbVie Donates $40 Million to Rebuild North Chicago Middle School
PR-M03-19-NI-066
Collaboration
New Collaboration Targets Parkinson’s Disease
PAO-M03-19-NI-005
FDA
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805
PR-M02-19-NI-025
«
0
3
»
.svg)
